We join our Editor-in-Chief, Peter Taylor (University of Oxford, Oxford, UK) to discuss a selection of abstracts presented at ACR 2021 investigating JAK inhibitors in the treatment of rheumatoid arthritis.Â
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
In Part 1, we discuss the JAK1 inhibitor, filgotinib, and the results from the 48 week extension of the FINCH 2 study (NCT03025308). In summary, efficacy maintained in refractory patients and safety is generally consistent.Â
The abstract entitled ‘Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial’ (Abstract Number: 1697) was presented at the ACR Convergence, 5-9 November 2021.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
